JP6412215B2 - 薬剤送達デバイスおよび薬物送達デバイス用作動機構 - Google Patents
薬剤送達デバイスおよび薬物送達デバイス用作動機構 Download PDFInfo
- Publication number
- JP6412215B2 JP6412215B2 JP2017124974A JP2017124974A JP6412215B2 JP 6412215 B2 JP6412215 B2 JP 6412215B2 JP 2017124974 A JP2017124974 A JP 2017124974A JP 2017124974 A JP2017124974 A JP 2017124974A JP 6412215 B2 JP6412215 B2 JP 6412215B2
- Authority
- JP
- Japan
- Prior art keywords
- outer sleeve
- delivery device
- drug delivery
- exendin
- inner sleeve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012377 drug delivery Methods 0.000 title claims description 28
- 230000007246 mechanism Effects 0.000 title claims description 15
- 239000003814 drug Substances 0.000 claims description 12
- 239000003086 colorant Substances 0.000 claims description 4
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 83
- 108010011459 Exenatide Proteins 0.000 description 49
- 229960001519 exenatide Drugs 0.000 description 49
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 22
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 21
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 11
- 239000012634 fragment Substances 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- -1 Carboxyheptadecanoyl Chemical group 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 206010069803 Injury associated with device Diseases 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229940090047 auto-injector Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 108010015174 exendin 3 Proteins 0.000 description 2
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 229960004532 somatropin Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 108010024118 Hypothalamic Hormones Proteins 0.000 description 1
- 102000015611 Hypothalamic Hormones Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical group OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 229940043650 hypothalamic hormone Drugs 0.000 description 1
- 239000000601 hypothalamic hormone Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940090048 pen injector Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/3257—Semi-automatic sleeve extension, i.e. in which triggering of the sleeve extension requires a deliberate action by the user, e.g. manual release of spring-biased extension means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2006—Having specific accessories
- A61M2005/2013—Having specific accessories triggering of discharging means by contact of injector with patient body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/3245—Constructional features thereof, e.g. to improve manipulation or functioning
- A61M2005/3247—Means to impede repositioning of protection sleeve from needle covering to needle uncovering position
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/326—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
- A61M2005/3267—Biased sleeves where the needle is uncovered by insertion of the needle into a patient's body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/60—General characteristics of the apparatus with identification means
- A61M2205/6063—Optical identification systems
- A61M2205/6081—Colour codes
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Environmental & Geological Engineering (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Description
ここで、一実施形態において、薬学的に活性な化合物は、最大1500Daまでの分子量を有し、および/または、ペプチド、タンパク質、多糖類、ワクチン、DNA、RNA、酵素、抗体もしくはそのフラグメント、ホルモンもしくはオリゴヌクレオチド、または上述の薬学的に活性な化合物の混合物であり、
ここで、さらなる実施形態において、薬学的に活性な化合物は、糖尿病、または糖尿病性網膜症などの糖尿病関連の合併症、深部静脈血栓塞栓症または肺血栓塞栓症などの血栓塞栓症、急性冠症候群(ACS)、狭心症、心筋梗塞、がん、黄斑変性症、炎症、枯草熱、アテローム性動脈硬化症および/または関節リウマチの処置および/または予防に有用であり、
ここで、さらなる実施形態において、薬学的に活性な化合物は、糖尿病または糖尿病性網膜症などの糖尿病に関連する合併症の処置および/または予防のための少なくとも1つのペプチドを含み、
ここで、さらなる実施形態において、薬学的に活性な化合物は、少なくとも1つのヒトインスリンもしくはヒトインスリン類似体もしくは誘導体、グルカゴン様ペプチド(GLP−1)もしくはその類似体もしくは誘導体、またはエキセンジン−3もしくはエキセンジン−4もしくはエキセンジン−3もしくはエキセンジン−4の類似体もしくは誘導体を含む。
インスリン;B29−N−(N−リトコリル−Y−グルタミル)−des(B30)ヒトインスリン;B29−N−(ω−カルボキシヘプタデカノイル)−des(B30)ヒトインスリン、およびB29−N−(ω−カルボキシヘプタデカノイル)ヒトインスリンである。
H−(Lys)4−desPro36,desPro37エキセンジン−4(1−39)−NH2、
H−(Lys)5−desPro36,desPro37エキセンジン−4(1−39)−NH2、
desPro36エキセンジン−4(1−39)、
desPro36[Asp28]エキセンジン−4(1−39)、
desPro36[IsoAsp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,Asp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,IsoAsp28]エキセンジン−(1−39)、
desPro36[Trp(O2)25,Asp28]エキセンジン−4(1−39)、
desPro36[Trp(O2)25,IsoAsp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(1−39)、
desPro36[Met(O)14Trp(O2)25,IsoAsp28]エキセンジン−4(1−39);または
desPro36[Asp28]エキセンジン−4(1−39)、
desPro36[IsoAsp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,Asp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,IsoAsp28]エキセンジン−(1−39)、
desPro36[Trp(O2)25,Asp28]エキセンジン−4(1−39)、
desPro36[Trp(O2)25,IsoAsp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(1−39)、
desPro36[Met(O)14,Trp(O2)25,IsoAsp28]エキセンジン−4(1−39)、
(ここで、基−Lys6−NH2が、エキセンジン−4誘導体のC−末端に結合していてもよい);
desPro36エキセンジン−4(1−39)−Lys6−NH2(AVE0010)、
H−(Lys)6−desPro36[Asp28]エキセンジン−4(1−39)−Lys6−NH2、
desAsp28Pro36,Pro37,Pro38エキセンジン−4(1−39)−NH2、
H−(Lys)6−desPro36,Pro38[Asp28]エキセンジン−4(1−39)−NH2、
H−Asn−(Glu)5desPro36,Pro37,Pro38[Asp28]エキセンジン−4(1−39)−NH2、
desPro36,Pro37,Pro38[Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−Asn−(Glu)5−desPro36,Pro37,Pro38[Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−(Lys)6−desPro36[Trp(O2)25,Asp28]エキセンジン−4(1−39)−Lys6−NH2、
H−desAsp28Pro36,Pro37,Pro38[Trp(O2)25]エキセンジン−4(1−39)−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Trp(O2)25,Asp28]エキセンジン−4(1−39)−NH2、
H−Asn−(Glu)5−desPro36,Pro37,Pro38[Trp(O2)25,Asp28]エキセンジン−4(1−39)−NH2、
desPro36,Pro37,Pro38[Trp(O2)25,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Trp(O2)25,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−Asn−(Glu)5−desPro36,Pro37,Pro38[Trp(O2)25,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−(Lys)6−desPro36[Met(O)14,Asp28]エキセンジン−4(1−39)−Lys6−NH2、
desMet(O)14,Asp28Pro36,Pro37,Pro38エキセンジン−4(1−39)−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Met(O)14,Asp28]エキセンジン−4(1−39)−NH2、
H−Asn−(Glu)5−desPro36,Pro37,Pro38[Met(O)14,Asp28]エキセンジン−4(1−39)−NH2;
desPro36,Pro37,Pro38[Met(O)14,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Met(O)14,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−Asn−(Glu)5desPro36,Pro37,Pro38[Met(O)14,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−Lys6−desPro36[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(1−39)−Lys6−NH2、
H−desAsp28,Pro36,Pro37,Pro38[Met(O)14,Trp(O2)25]エキセンジン−4(1−39)−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Met(O)14,Asp28]エキセンジン−4(1−39)−NH2、
H−Asn−(Glu)5−desPro36,Pro37,Pro38[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(1−39)−NH2、
desPro36,Pro37,Pro38[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2、
H−(Lys)6−desPro36,Pro37,Pro38[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(S1−39)−(Lys)6−NH2、
H−Asn−(Glu)5−desPro36,Pro37,Pro38[Met(O)14,Trp(O2)25,Asp28]エキセンジン−4(1−39)−(Lys)6−NH2;
または前述のいずれか1つのエキセンジン−4誘導体の薬学的に許容される塩もしくは溶媒和化合物
から選択される。
いて、定常領域は、同じアイソタイプのすべての抗体で本質的に同一であるが、異なるアイソタイプの抗体では異なる。重鎖γ、α、およびδは、3つのタンデム型のIgドメインと、可撓性を加えるためのヒンジ領域とから構成される定常領域を有し、重鎖μおよびεは、4つの免疫グロブリン・ドメインから構成される定常領域を有する。重鎖の可変領域は、異なるB細胞によって産生された抗体では異なるが、単一B細胞またはB細胞クローンによって産生された抗体すべてについては同じである。各重鎖の可変領域は、約110アミノ酸長であり、単一のIgドメインから構成される。
あろう。しかし、この詳細な説明から、本発明の趣旨および範囲に含まれるさまざまな変更および修正が当業者に明らかになるので、詳細な説明および具体的な例は、本発明の好ましい実施形態を示しているが、例示として与えられるものにすぎないことを理解されたい。
することができ、かつ外側スリーブ4は、第1の状態で第2のばね要素によって付勢することができる。
まな構成要素の修正(追加および/または除去)は本発明のすべての範囲および趣旨から逸脱することなく行うことができ、このような修正およびそのあらゆる等価物を包含することは、当業者には理解されよう。
Claims (9)
- 遠位先端(2.1)を備えた針(2)を有する薬剤送達デバイス(1)であって、
ハウジング(5)と、
ハウジング(5)に対して嵌め込み式にされ、ハウジング(5)に対して軸方向に並進運動可能な外側スリーブ(4)と、外側スリーブ(4)に対して嵌め込み式に配置され、外側スリーブ(4)に対して軸方向に並進運動可能な内側スリーブ(3)とを備えた作動機構と、
を備え、
ここで、第1の状態では、内側スリーブ(3)は外側スリーブ(4)から遠位方向に突出し、外側スリーブ(4)はハウジング(5)から遠位方向に突出し、内側スリーブ(3)及び外側スリーブ(4)は針(2)の遠位先端(2.1)を覆い、
第2の状態では、内側スリーブ(3)は外側スリーブ(4)の中に含まれ、
前記第2の状態において、外側スリーブ(4)がハウジング(5)に対して近位方向へ動くことが、薬物送達デバイス(1)での薬剤の送達を可能にするために必要である、
上記薬物送達デバイス。 - 内側スリーブ(3)および外側スリーブ(4)は異なる色またはしるしを有する、請求項1に記載の薬物送達デバイス(1)。
- 第1の状態では、外側スリーブ(4)はハウジング(5)に対して位置固定される、請求項1又は2に記載の薬物送達デバイス(1)。
- 第2の状態では、内側スリーブ(3)は外側スリーブ(4)と係合する、請求項1〜3のいずれか1項に記載の薬物送達デバイス(1)。
- 内側スリーブ(3)は、外側スリーブ(4)内の凹部または開口部と係合するように適合された掛止具を含む、請求項4に記載の薬物送達デバイス(1)。
- 外側スリーブ(4)は、内側スリーブ(3)内の凹部または開口部と係合するように適
合された掛止具を含む、請求項4に記載の薬物送達デバイス(1)。 - 第3の状態にあるとき、内側スリーブ(3)は外側スリーブ(4)に対してロックされ、外側スリーブ(4)はハウジング(5)に対してロックされる、請求項1〜6のいずれか1項に記載の薬物送達デバイス(1)。
- 第2の状態では、針(2)の遠位先端(2.1)は、外側スリーブ(4)に対して遠位方向に突出するように適合される、請求項1〜7のいずれか1項に記載の薬物送達デバイス(1)。
- 第3の状態では、内側スリーブ(3)および/または外側スリーブ(4)は針(2)の遠位先端(2.1)を覆う、請求項7又は8に記載の薬物送達デバイス(1)。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11182632A EP2572741A1 (en) | 2011-09-23 | 2011-09-23 | Medicament delivery device and actuation mechanism for a drug delivery device |
EP11182632.7 | 2011-09-23 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014531235A Division JP6169575B2 (ja) | 2011-09-23 | 2012-09-20 | 薬剤送達デバイスおよび薬物送達デバイス用作動機構 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017196460A JP2017196460A (ja) | 2017-11-02 |
JP6412215B2 true JP6412215B2 (ja) | 2018-10-24 |
Family
ID=46875853
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014531235A Active JP6169575B2 (ja) | 2011-09-23 | 2012-09-20 | 薬剤送達デバイスおよび薬物送達デバイス用作動機構 |
JP2017124974A Active JP6412215B2 (ja) | 2011-09-23 | 2017-06-27 | 薬剤送達デバイスおよび薬物送達デバイス用作動機構 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014531235A Active JP6169575B2 (ja) | 2011-09-23 | 2012-09-20 | 薬剤送達デバイスおよび薬物送達デバイス用作動機構 |
Country Status (6)
Country | Link |
---|---|
US (9) | US9364617B2 (ja) |
EP (4) | EP2572741A1 (ja) |
JP (2) | JP6169575B2 (ja) |
CA (1) | CA2848101A1 (ja) |
DK (2) | DK3225268T3 (ja) |
WO (1) | WO2013041642A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2572741A1 (en) | 2011-09-23 | 2013-03-27 | Sanofi-Aventis Deutschland GmbH | Medicament delivery device and actuation mechanism for a drug delivery device |
CN104254355B (zh) | 2011-11-07 | 2018-04-24 | 安全注射器有限公司 | 接触触发器释放的护针器 |
CA2910081A1 (en) | 2013-06-18 | 2014-12-24 | Enable Injections, Llc | Vial transfer and injection apparatus and method |
EP3943135A3 (en) | 2014-10-14 | 2022-06-29 | Amgen Inc. | Drug injection device with visual and audible indicators |
FR3056915B1 (fr) | 2016-10-04 | 2021-12-17 | Aptar France Sas | Dispositif d'injection manuelle. |
CN110325231B (zh) | 2016-12-27 | 2020-10-02 | 阿克申医药科技有限公司 | 用于注射药物的设备和方法 |
US11464917B2 (en) | 2017-10-30 | 2022-10-11 | Sanofi | Injector device |
US11224696B2 (en) | 2018-07-10 | 2022-01-18 | Action Medical Technologies, Llc | Apparatuses and method for injecting medicaments |
USD893712S1 (en) | 2019-02-15 | 2020-08-18 | Action Medical Technologies, Llc | Grip for autoinjectors |
CA3172305C (en) | 2020-03-25 | 2023-02-07 | Joseph B. Hoffer | Apparatuses and methods for injecting medicaments |
US11759576B2 (en) | 2020-06-05 | 2023-09-19 | Action Medical Technologies, Llc | Parenteral injection apparatus |
CN111658902A (zh) * | 2020-07-21 | 2020-09-15 | 四川大学 | 一种安全的自动化药物注射装置 |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4487602A (en) * | 1981-09-14 | 1984-12-11 | Syntex (U.S.A.) Inc. | Injection device |
US4378015A (en) * | 1981-12-21 | 1983-03-29 | Wardlaw Stephen C | Automatic injecting syringe |
US5248301A (en) * | 1987-12-03 | 1993-09-28 | Medfusion, Inc. | Transcutaneous infusion apparatus and methods of manufacture and use |
US4897083A (en) * | 1988-05-09 | 1990-01-30 | Martell Michael D | Syringe needle guard |
US4902279A (en) * | 1988-10-05 | 1990-02-20 | Autoject Systems Inc. | Liquid medicament safety injector |
US5271744A (en) * | 1991-04-29 | 1993-12-21 | George C. Kramer | System and method for rapid vascular drug delivery |
US5176643A (en) * | 1991-04-29 | 1993-01-05 | George C. Kramer | System and method for rapid vascular drug delivery |
US5451210A (en) * | 1991-04-29 | 1995-09-19 | Lifequest Medical, Inc. | System and method for rapid vascular drug delivery |
US5681291A (en) * | 1992-11-19 | 1997-10-28 | Tebro S.A. | Disposable auto-injector for prefilled syringes |
DE69427226T2 (de) * | 1993-03-24 | 2001-08-30 | Owen Mumford Ltd., Woodstock | Vorrichtung zur injektion |
US5336199A (en) * | 1993-11-12 | 1994-08-09 | Castillo Leo S | Medical needle and needle sheath assembly |
US5478316A (en) * | 1994-02-02 | 1995-12-26 | Becton, Dickinson And Company | Automatic self-injection device |
FR2733155B1 (fr) * | 1995-04-18 | 1997-09-19 | Tebro | Auto-injecteur rechargeable |
US5658259A (en) * | 1995-10-19 | 1997-08-19 | Meridian Medical Technologies, Inc. | Dental cartridge assembly auto-injector with protective needle cover |
US5609577A (en) * | 1996-01-29 | 1997-03-11 | Haber; Terry M. | Automatically locking hypodermic needle hiding shield for a dose metering syringe |
IE970782A1 (en) * | 1997-10-22 | 1999-05-05 | Elan Corp | An improved automatic syringe |
FR2774294B1 (fr) * | 1998-02-04 | 2000-04-14 | Marc Brunel | Dispositif d'injection automatique d'une dose de produit medicamenteux |
DE19822031C2 (de) * | 1998-05-15 | 2000-03-23 | Disetronic Licensing Ag | Autoinjektionsgerät |
US6162197A (en) * | 1998-12-22 | 2000-12-19 | Mohammad; Owais | Retractable needle assembly and method of making the same |
US20050171486A1 (en) * | 1999-05-10 | 2005-08-04 | Hochman Mark N. | Safety syringe |
US20010031949A1 (en) * | 1999-06-18 | 2001-10-18 | Asbaghi Hooman A. | Protective device for a prefilled injection syringe |
US6102896A (en) * | 1999-09-08 | 2000-08-15 | Cambridge Biostability Limited | Disposable injector device |
DE10009815B4 (de) * | 2000-03-01 | 2009-07-16 | Tecpharma Licensing Ag | Injektionsgerät mit einer Nadelabdeckung |
DE10044383C2 (de) * | 2000-09-08 | 2003-02-06 | Disetronic Licensing Ag | Nadelschutzvorrichtung |
CA2468243C (en) * | 2001-11-30 | 2010-08-03 | Novo Nordisk A/S | A safety needle assembly |
WO2003077968A2 (en) * | 2002-03-13 | 2003-09-25 | Eli Lilly And Company | Method of treating a medical condition with a portable medication delivery device |
US6808507B2 (en) * | 2002-05-10 | 2004-10-26 | Cambridge Biostability Ltd. | Safety injectors |
US7083600B2 (en) * | 2002-08-08 | 2006-08-01 | Advanced Medical Sharps, Inc. | Safety needle and shield |
AT413648B (de) * | 2002-10-02 | 2006-04-15 | Greiner Bio One Gmbh | Aufnahmevorrichtung mit verstellbarem abdeckelement |
JP4339260B2 (ja) * | 2002-11-25 | 2009-10-07 | テクファーマ・ライセンシング・アクチェンゲゼルシャフト | 針保護装置を有する注射装置 |
US6767336B1 (en) * | 2003-01-09 | 2004-07-27 | Sheldon Kaplan | Automatic injector |
US6805686B1 (en) * | 2003-05-06 | 2004-10-19 | Abbott Laboratories | Autoinjector with extendable needle protector shroud |
MXPA06002047A (es) * | 2003-08-28 | 2006-05-25 | Becton Dickinson Co | Dispositivo de inyeccion intradermico. |
DE10342058B4 (de) * | 2003-09-11 | 2007-10-25 | Tecpharma Licensing Ag | Verabreichungsvorrichtung für ein injizierbares Produkt mit einer Auslösesicherung |
DE10342059B4 (de) * | 2003-09-11 | 2007-03-01 | Tecpharma Licensing Ag | Verabreichungsvorrichtung mit Einstech- und Ausschütteinrichtung |
GB0406458D0 (en) * | 2003-10-09 | 2004-04-28 | Liversidge Barry P | Safety medical needle assemblies |
US7635348B2 (en) * | 2003-11-04 | 2009-12-22 | Meridian Medical Technologies, Inc. | Container for medicament automatic injector and automatic injector adapted therefor |
DE10351599A1 (de) * | 2003-11-05 | 2005-06-16 | Tecpharma Licensing Ag | Autoinjektionsvorrichtung |
GB0327136D0 (en) * | 2003-11-21 | 2003-12-24 | Nmt Group Plc | Safety needle |
CH696421A5 (de) * | 2003-12-18 | 2007-06-15 | Tecpharma Licensing Ag | Autoinjektor mit Arretierung des Wirkstoffbehälters. |
WO2005058396A1 (de) * | 2003-12-18 | 2005-06-30 | Tecpharma Licensing Ag | Auslösbares injektionsgerät |
GB0403335D0 (en) * | 2004-02-14 | 2004-03-17 | Liversidge Barry P | Medical injector handling device |
GB2414403B (en) * | 2004-05-28 | 2009-01-07 | Cilag Ag Int | Injection device |
GB2414399B (en) * | 2004-05-28 | 2008-12-31 | Cilag Ag Int | Injection device |
US8048035B2 (en) * | 2004-08-06 | 2011-11-01 | Meridian Medical Technologies, Inc. | Automatic injector with needle cover |
DE102004053529A1 (de) * | 2004-11-05 | 2006-05-11 | Tecpharma Licensing Ag | Blutentnahmesystem |
EP1666085A1 (fr) * | 2004-12-01 | 2006-06-07 | Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S) SAS | Dispositif d'injection d'un implant solide ou semi-solide |
GB2424838B (en) * | 2005-04-06 | 2011-02-23 | Cilag Ag Int | Injection device (adaptable drive) |
ES2677022T3 (es) * | 2005-04-20 | 2018-07-27 | Becton Dickinson France | Conjunto de inyección y dispositivo de asistencia de inyección |
FR2884722A1 (fr) * | 2005-04-20 | 2006-10-27 | Becton Dickinson France Soc Pa | Ensemble d'injection et dispositif d'assistance |
GB2438590B (en) * | 2006-06-01 | 2011-02-09 | Cilag Gmbh Int | Injection device |
BRPI0720777A2 (pt) * | 2006-12-22 | 2014-07-01 | Novo Nordisk As | Conjunto de agulha capaz de ser protegido com protetor inclinado de segurança |
US7540858B2 (en) * | 2007-01-23 | 2009-06-02 | Becton, Dickinson And Company | Retracting safety pen needle |
ES2585935T3 (es) * | 2007-03-07 | 2016-10-10 | Becton Dickinson And Company | Conjunto de seguridad de recogida de sangre con indicador |
WO2008112472A2 (en) * | 2007-03-09 | 2008-09-18 | Eli Lilly And Company | Delay mechanism for automatic injection device |
CN101678168B (zh) * | 2007-03-22 | 2013-03-06 | 特克法马许可公司 | 具有受控制的注射针拉回功能的注射装置 |
US8500693B2 (en) * | 2007-09-25 | 2013-08-06 | Becton Dickinson France | Autoinjector received in external socket |
CA2719109C (en) * | 2008-03-13 | 2015-11-24 | Becton, Dickinson And Company | Safety pen needle assembly having shielding for patient and non-patient ends |
WO2009114777A1 (en) * | 2008-03-13 | 2009-09-17 | Becton, Dickinson And Company | Safety needle assembly |
GB2461086B (en) * | 2008-06-19 | 2012-12-05 | Cilag Gmbh Int | Injection device |
WO2010142641A1 (de) * | 2009-06-10 | 2010-12-16 | V. KRÜTTEN MEDIZINISCHE EINMALGERÄTE GmbH | Portkanüle mit nadelstichschutzvorrichtung |
JP5279953B2 (ja) * | 2009-08-21 | 2013-09-04 | エス・ホー・エル・グループ・アクチボラゲット | 安全ペン型注射針装置 |
SG10201912277VA (en) * | 2009-10-16 | 2020-02-27 | Janssen Biotech Inc | Palm activated drug delivery device |
JP5763654B2 (ja) * | 2009-10-21 | 2015-08-12 | オウエン マンフォード リミティド | 自動注射器 |
BR112012019101A2 (pt) * | 2010-02-05 | 2016-09-13 | Sanofi Aventis Deutschland | módulo medicamentoso com botão de uso duplo e sistema de fornecimento de medicamento. |
EP2399635A1 (en) * | 2010-06-28 | 2011-12-28 | Sanofi-Aventis Deutschland GmbH | Auto-injector |
WO2012022810A2 (en) * | 2010-08-19 | 2012-02-23 | Novo Nordisk A/S | Medical injection device |
GB201020475D0 (en) * | 2010-12-02 | 2011-01-19 | Oval Medical Technologies Ltd | Delivery mechanism for an autoinjector |
EP2661298B1 (en) * | 2011-01-04 | 2019-10-02 | Sanofi-Aventis Deutschland GmbH | Safety device and injection device |
EP2489390A1 (en) * | 2011-02-18 | 2012-08-22 | Sanofi-Aventis Deutschland GmbH | Detent mechanism |
US9775948B2 (en) * | 2011-09-09 | 2017-10-03 | Merck Patent Gmbh | Auto injector with separate needle injection |
EP2572741A1 (en) | 2011-09-23 | 2013-03-27 | Sanofi-Aventis Deutschland GmbH | Medicament delivery device and actuation mechanism for a drug delivery device |
WO2013154954A1 (en) * | 2012-04-11 | 2013-10-17 | Thomas Jefferson University | Hypodermic injection device incorporated in a case for a portable electronic device |
US9364611B2 (en) * | 2012-05-07 | 2016-06-14 | Antares Pharma, Inc. | Needle assisted jet injection device having reduced trigger force |
US9931467B2 (en) * | 2012-05-25 | 2018-04-03 | Aptar France Sas | Autoinjector |
EP2703029A1 (en) * | 2012-09-04 | 2014-03-05 | Sanofi-Aventis Deutschland GmbH | Medicament delivery device with alignment mechanism |
EP2703026A1 (en) * | 2012-09-04 | 2014-03-05 | Sanofi-Aventis Deutschland GmbH | Safety needle assembly |
US9125985B2 (en) * | 2013-04-01 | 2015-09-08 | iMed Technology, Inc. | Needle with protective cover member |
CN110325231B (zh) * | 2016-12-27 | 2020-10-02 | 阿克申医药科技有限公司 | 用于注射药物的设备和方法 |
-
2011
- 2011-09-23 EP EP11182632A patent/EP2572741A1/en not_active Ceased
-
2012
- 2012-09-20 DK DK17166144.0T patent/DK3225268T3/da active
- 2012-09-20 EP EP17166144.0A patent/EP3225268B1/en active Active
- 2012-09-20 CA CA2848101A patent/CA2848101A1/en not_active Abandoned
- 2012-09-20 JP JP2014531235A patent/JP6169575B2/ja active Active
- 2012-09-20 US US14/346,228 patent/US9364617B2/en active Active
- 2012-09-20 EP EP24180835.1A patent/EP4434562A2/en active Pending
- 2012-09-20 EP EP12759761.5A patent/EP2758099B1/en active Active
- 2012-09-20 WO PCT/EP2012/068572 patent/WO2013041642A1/en active Application Filing
- 2012-09-20 DK DK12759761.5T patent/DK2758099T3/en active
-
2016
- 2016-06-09 US US15/177,948 patent/US10675408B2/en active Active
-
2017
- 2017-06-27 JP JP2017124974A patent/JP6412215B2/ja active Active
-
2020
- 2020-06-03 US US16/892,047 patent/US20200306449A1/en active Pending
- 2020-09-03 US US17/011,607 patent/US11918786B2/en active Active
-
2024
- 2024-06-28 US US18/757,683 patent/US20240350730A1/en active Pending
- 2024-06-28 US US18/757,999 patent/US20240350732A1/en active Pending
- 2024-06-28 US US18/757,728 patent/US20240350731A1/en active Pending
- 2024-06-28 US US18/758,133 patent/US20240350733A1/en active Pending
- 2024-06-28 US US18/757,830 patent/US20240342375A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200397992A1 (en) | 2020-12-24 |
EP2572741A1 (en) | 2013-03-27 |
DK2758099T3 (en) | 2017-09-11 |
EP3225268B1 (en) | 2024-07-17 |
JP2017196460A (ja) | 2017-11-02 |
DK3225268T3 (da) | 2024-09-09 |
EP3225268A1 (en) | 2017-10-04 |
US9364617B2 (en) | 2016-06-14 |
EP4434562A2 (en) | 2024-09-25 |
US20240342375A1 (en) | 2024-10-17 |
JP6169575B2 (ja) | 2017-07-26 |
US20240350733A1 (en) | 2024-10-24 |
US20240350730A1 (en) | 2024-10-24 |
CA2848101A1 (en) | 2013-03-28 |
US20140236094A1 (en) | 2014-08-21 |
US11918786B2 (en) | 2024-03-05 |
JP2014526357A (ja) | 2014-10-06 |
WO2013041642A1 (en) | 2013-03-28 |
US20240350731A1 (en) | 2024-10-24 |
EP2758099A1 (en) | 2014-07-30 |
US20200306449A1 (en) | 2020-10-01 |
US20160287787A1 (en) | 2016-10-06 |
US10675408B2 (en) | 2020-06-09 |
US20240350732A1 (en) | 2024-10-24 |
EP2758099B1 (en) | 2017-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6412215B2 (ja) | 薬剤送達デバイスおよび薬物送達デバイス用作動機構 | |
JP6618466B2 (ja) | 薬剤送達デバイス | |
JP6622694B2 (ja) | 2つの駆動ばねを備えた薬剤送達デバイス | |
JP6408571B2 (ja) | 自動注射器 | |
JP6043806B2 (ja) | 自動注射器 | |
JP6412121B2 (ja) | 自己注射器(Autoinjector) | |
JP6261519B2 (ja) | 固定用量薬剤送達デバイス | |
JP6415441B2 (ja) | 自動注射器 | |
JP6043805B2 (ja) | 外側プランジャと係合解除してシリンジ・キャリアを後退させる内側プランジャ付きの自動注射器 | |
JP6577942B2 (ja) | 注射デバイス | |
JP6367796B2 (ja) | 薬物送達デバイス | |
JP6328121B2 (ja) | 薬剤送達開始インジケータを備えた薬剤送達デバイス | |
JP6487428B2 (ja) | 自動注射器(Autoinjector) | |
JP6326054B2 (ja) | 使用状態インジケータを備える薬剤送達デバイス | |
JP2014503302A (ja) | プレフィルドシリンジと注射デバイス用の安全デバイス | |
JP2015522363A (ja) | 薬物送達デバイス | |
JP6637416B2 (ja) | 自動注射器 | |
JP2017504422A (ja) | 薬剤送達デバイス | |
JP6556152B2 (ja) | 流体を投与するための針 | |
JP6313308B2 (ja) | 位置合わせ機構を備えた薬剤送達デバイス | |
JP2016540577A (ja) | 針安全デバイスおよび薬物送達デバイス |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180427 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180529 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180801 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180904 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180927 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6412215 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |